ArticleJournal of clinical microbiology2015
Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.
Abstract read
In one paragraph
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Optimising pyrazinamide for the treatment of tuberculosis.The European respiratory journal · 2021Trial
- Algorithmic Determinants of Performance Heterogeneity in Whole-Genome Sequencing-Based Prediction of Drug Resistance inMicroorganisms · 2026Review
- Comprehensive evaluation of the MeltPro MTB/PZA assay for prediction of pyrazinamide resistance in multidrug-resistant tuberculosis.Microbiology spectrum · 2025Article
- Prediction of pyrazinamide resistance inJAC-antimicrobial resistance · 2024Article
- Activity of Pyrazinamide againstAntibiotics (Basel, Switzerland) · 2021Article
- Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis.Nature medicine · 2020Article
- How To Optimally Combine Genotypic and Phenotypic Drug Susceptibility Testing Methods for Pyrazinamide.Antimicrobial agents and chemotherapy · 2020Article
- Rapid Pyrazinamide Drug Susceptibility Testing using a Closed-Tube PCR Assay of the Entire pncA gene.Scientific reports · 2020Article
- Structure guided prediction of Pyrazinamide resistance mutations in pncA.Scientific reports · 2020Article
- Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.BMC infectious diseases · 2020Article
- Article
- Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use ofJournal of clinical microbiology · 2019Article
- Rapid microarray-based assay for detection of pyrazinamide resistant Mycobacterium tuberculosis.Diagnostic microbiology and infectious disease · 2019Article
- Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.The Lancet. Infectious diseases · 2018Article
- Detection ofAntimicrobial agents and chemotherapy · 2018Article
- Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2018Article
- A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide.Nature communications · 2017Article
- Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.The Journal of antimicrobial chemotherapy · 2017Review
- A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis.Scientific reports · 2017Article
- Comprehensive Whole-Genome Sequencing and Reporting of Drug Resistance Profiles on Clinical Cases of Mycobacterium tuberculosis in New York State.Journal of clinical microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Michael G WhitfieldSA MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Robin M WarrenSA MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa rw1@sun.ac.za.
Elizabeth M StreicherSA MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Samantha L SampsonSA MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Frik A SirgelSA MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Paul D van HeldenSA MRC Centre for Tuberculosis Research, DST/NRF Centre of Excellence for Biomedical TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa.
Alexandra MercanteDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Melisa WillbyDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kelsey HughesDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Kris BirknessDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Glenn MorlockDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Annelies van RieDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
James E PoseyDivision of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Funding
Optimizing the impact of Xpert MTB/RIF on treatment outcomes of drug resistant TBR01AI099026 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAN RIE, ANNELIES T.A. · 2012 to 2014
$1.6MNIAID NIH HHS R01 AI099026NIAID NIH HHS R01AI099026PHS HHS AAI12052-0001-00000
Abstract
Sequencing of the Mycobacterium tuberculosis pncA gene allows for pyrazinamide susceptibility testing. We summarize data on pncA polymorphisms that do not confer resistance at a susceptibility breakpoint of 100 μg/ml pyrazinamide in MGIT within a cohort of isolates from South Africa and the U.S. Centers for Disease Control and Prevention.
Indexed as
AmidohydrolasesAntitubercular AgentsBase SequenceDNA, BacterialDrug Resistance, BacterialHumansMicrobial Sensitivity TestsMycobacterium tuberculosisPolymorphism, Single NucleotidePyrazinamideSequence Analysis, DNASouth AfricaUnited StatesAmidohydrolasesAntitubercular AgentsDNA, BacterialPncA protein, Mycobacterium tuberculosisPyrazinamidepyrazinamide deamidase
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.